A Study of Retatrutide (LY3437943) in Adults With Obesity and Established Cardiovascular Disease (TRIUMPH-3)
View Source THE LANCET Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes A Phase 2 Trial 2023 Rosenstock J, et al
Compounded semaglutide, though available as an alternative during shortages, lacks FDA approval and standardized dosing, raising safety and effectiveness concerns
Bowel Obstruction: This is a physical blockage in the small or large intestine
Retail pharmacy pricing frequently exceeds $1,300 per month depending on dosage strength, pharmacy location, and available discounts
24+ Months: Long-Term Maintenance Decision At this point, patients and their physician make a shared decision: attempt a carefully managed tapering and transition to maintenance, or continue long-term medication for ongoing metabolic management